[Click here to JOIN and get our WEEKLY newsletter!!]

Shire plans to expand in the US
Financial Times (subscription), UK - Jul 31, 2003
... to $299m while earnings per share was 10 per cent higher at 12.8c. Adderall XR, its
new hyperactivity drug, withstood competition from Eli Lilly's Strattera to ...

ADHD in adults: A child's diagnosis often leads to parent's ...
Greenville News, SC - Jul 28, 2003
... But when Strattera was approved by the FDA last November, the first non-stimulant
ADHD drug on the market was wildly successful, Beard said. ...

Media Advisory - New treatment option for ADHD welcomed
Canada NewsWire (press release), Canada - Jul 28, 2003
Another compound, atomoxetine (brand name Strattera(TM)), became the first non-stimulant
treatment approved for ADHD in the United States on November, 2002. ...

Zyprexa sales pace solid quarter at Lilly
Indianapolis Star, IN - Jul 24, 2003
... quarter. They are Forteo for osteoporosis, Strattera for attention
deficit/hyperactivity disorder, and Cialis for male impotence. ...

Lilly posts 5 percent earnings gain in 2Q
Seattle Post Intelligencer, WA - Jul 24, 2003
... The performance was bolstered by strong initial sales of Strattera,
a new medication for attention deficit hyperactivity disorder. ...

Lilly Posts 5 Percent Earnings Gain in 2Q
ABC News - Jul 24, 2003
The performance was bolstered by strong initial sales of Strattera,
a new medication for attention deficit hyperactivity disorder. ...

Lilly Posts 5 Percent Earnings Gain in 2Q
Austin American Statesman, TX - Jul 24, 2003
... The performance was bolstered by strong initial sales of Strattera,
a new medication for attention deficit hyperactivity disorder. ...

Lilly Posts 5 Percent Earnings Gain in 2Q
Atlanta Journal Constitution, GA - Jul 24, 2003
... The performance was bolstered by strong initial sales of Strattera,
a new medication for attention deficit hyperactivity disorder. ...

Eli Lilly Profits Helped by Zyprexa
MSN Money - Jul 24, 2003
... Total company sales rose 11 percent to $3.09 billion in the quarter, also boosted
by its osteoporosis drug Evista and the company's recently launched Strattera ...

Eli Lilly Profits Helped by Zyprexa
Reuters, UK - Jul 24, 2003
... Total company sales rose 11 percent to $3.09 billion in the quarter, also boosted
by its osteoporosis drug Evista and the company's recently launched Strattera ...

Eli Lilly Profits Helped by Zyprexa
Reuters, UK - Jul 24, 2003
... Total company sales rose 11 percent to $3.09 billion in the quarter, also boosted
by its osteoporosis drug Evista and the company's recently launched Strattera ...

Earnings roundup
Baltimore Sun, MD - Jul 24, 2003
... The performance was bolstered by strong initial sales of Strattera,
a new medication for attention deficit hyperactivity disorder. ...

Lilly Posts 5 Percent Earnings Gain in 2Q
Austin American Statesman, TX - Jul 24, 2003
... The performance was bolstered by strong initial sales of Strattera,
a new medication for attention deficit hyperactivity disorder. ...

Lilly Posts 5 Percent Earnings Gain in 2Q
Atlanta Journal Constitution, GA - Jul 24, 2003
... The performance was bolstered by strong initial sales of Strattera,
a new medication for attention deficit hyperactivity disorder. ...

UPDATE 3-Eli Lilly quarterly profit up, helped by Zyprexa
Reuters, UK - Jul 24, 2003
... Total company sales rose 11 percent to $3.09 billion in the quarter, also boosted
by its osteoporosis drug Evista and the company's recently launched Strattera ...

Lilly Posts 5% Earnings Gain, Beats Wall Street
WISH, IN - Jul 24, 2003
The performance was bolstered by strong initial sales of Strattera,
a new medication for Attention Deficit Hyperactivity Disorder. ...

Eli Lilly Profit Rises, Helped by Zyprexa
FOX News - Jul 24, 2003
... sales rose 11 percent to $3.09 billion in the quarter, also boosted by its osteoporosis
drug Evista (search) and the company's recently launched Strattera ...

Eli Lilly Profit Rises, Helped by Zyprexa
Washington Post, DC - Jul 24, 2003
... Total company sales rose 11 percent to $3.09 billion in the quarter, also boosted
by its osteoporosis drug Evista and the company's recently launched Strattera ...

Lilly Posts 5 Percent Earnings Gain in 2Q
Wilmington Morning Star, NC - Jul 24, 2003
... The performance was bolstered by strong initial sales of Strattera,
a new medication for attention deficit hyperactivity disorder. ...

Eli Lilly Profit Rises, Helped by Zyprexa
MSN Money - Jul 24, 2003
... Total company sales rose 11 percent to $3.09 billion in the quarter, also boosted
by its osteoporosis drug Evista and the company's recently launched Strattera ...

Lilly Posts 5 Percent Earnings Gain in 2Q
Austin American Statesman, TX - Jul 24, 2003
... The performance was bolstered by strong initial sales of Strattera,
a new medication for attention deficit hyperactivity disorder. ...

Lilly Posts 5 Percent Earnings Gain in 2Q
Atlanta Journal Constitution, GA - Jul 24, 2003
... The performance was bolstered by strong initial sales of Strattera,
a new medication for attention deficit hyperactivity disorder. ...

Eli Lilly Profit Rises, Helped by Zyprexa
Reuters, UK - Jul 24, 2003
... Total company sales rose 11 percent to $3.09 billion in the quarter, also boosted
by its osteoporosis drug Evista and the company's recently launched Strattera ...

Lilly posts 5 percent earnings gain
Indianapolis Star, IN - Jul 24, 2003
The performance was bolstered by strong initial sales of Strattera,
a new medication for attention deficit hyperactivity disorder. ...

Lilly Posts 5 Percent Earnings Gain in 2Q
Newsday - Jul 24, 2003
... The performance was bolstered by strong initial sales of Strattera,
a new medication for attention deficit hyperactivity disorder. ...

Lilly posts 5 percent earnings gain in 2Q
Penn Live, PA - Jul 24, 2003
... The performance was bolstered by strong initial sales of Strattera,
a new medication for attention deficit hyperactivity disorder. ...

Lilly Posts 5 Percent Earnings Gain in 2Q
Times Daily, AL - Jul 24, 2003
... The performance was bolstered by strong initial sales of Strattera,
a new medication for attention deficit hyperactivity disorder. ...

Lilly Posts 5 Percent Earnings Gain in 2Q
San Jose Mercury News, CA - Jul 24, 2003
The performance was bolstered by strong initial sales of Strattera,
a new medication for attention deficit hyperactivity disorder. ...

Lilly Posts 5 Percent Earnings Gain in 2Q
Sarasota Herald-Tribune, FL - Jul 24, 2003
... The performance was bolstered by strong initial sales of Strattera,
a new medication for attention deficit hyperactivity disorder. ...

Lilly posts 5 percent earnings gain, beats Wall Street
Kansas City Star, MO - Jul 24, 2003
The performance was bolstered by strong initial sales of Strattera,
a new medication for attention deficit hyperactivity disorder. ...

Lilly posts 5 percent earnings gain, beats Wall Street
Miami Herald, FL - Jul 24, 2003
The performance was bolstered by strong initial sales of Strattera,
a new medication for attention deficit hyperactivity disorder. ...

Lilly posts 5 percent earnings gain, beats Wall Street
Akron Beacon Journal, OH - Jul 24, 2003
The performance was bolstered by strong initial sales of Strattera,
a new medication for attention deficit hyperactivity disorder. ...

Lilly posts 5 percent earnings gain, beats Wall Street
Fort Wayne News Sentinel, IN - Jul 24, 2003
The performance was bolstered by strong initial sales of Strattera,
a new medication for attention deficit hyperactivity disorder. ...

Lilly posts 5 percent earnings gain, beats Wall Street
Wichita Eagle, KS - Jul 24, 2003
The performance was bolstered by strong initial sales of Strattera,
a new medication for attention deficit hyperactivity disorder. ...

Ex-Aide of Helms Joins Former Foe's Firm
Washington Post, DC - Jul 23, 2003
... She could not be reached for comment yesterday. Steelman was succeeded by
Anne Nobles, who had been the company's Strattera product team leader. ...

Only FDA-approved Nonstimulant for ADHD Reaches 12.9 Percent ...
Business Wire (press release) - Jul 22, 2003
In just six months, physicians have written more than 1 million prescriptions for
Strattera(R) (atomoxetine HCl), the only nonstimulant medicine approved for ...

Lilly's Strattera passes 1 million prescription mark
Wichita Eagle, KS - Jul 22, 2003
INDIANAPOLIS - Eli Lilly & Co.'s Strattera has claimed 13 percent of the US market
for drugs that treat attention-deficit hyperactivity disorder since it was ...

Lilly's Strattera passes 1 million prescription mark
Fort Wayne News Sentinel, IN - Jul 22, 2003
INDIANAPOLIS - Eli Lilly & Co.'s Strattera has claimed 13 percent of the US market
for drugs that treat attention-deficit hyperactivity disorder since it was ...

Lilly's Strattera passes 1 million prescription mark
Miami Herald, FL - Jul 22, 2003
INDIANAPOLIS - Eli Lilly & Co.'s Strattera has claimed 13 percent of the US market
for drugs that treat attention-deficit hyperactivity disorder since it was ...

Lilly's Strattera passes 1 million prescription mark
Kansas City Star, MO - Jul 22, 2003
INDIANAPOLIS - Eli Lilly & Co.'s Strattera has claimed 13 percent of the US market
for drugs that treat attention-deficit hyperactivity disorder since it was ...

Lilly's Strattera passes 1 million prescription mark
Akron Beacon Journal, OH - Jul 22, 2003
INDIANAPOLIS - Eli Lilly & Co.'s Strattera has claimed 13 percent of the US market
for drugs that treat attention-deficit hyperactivity disorder since it was ...

Adult ADD: Common disorder or marketing ploy?
CNN - Jul 18, 2003
... Institute of Health. Eli Lilly's TV and radio ads about adult ADD and
its drug Strattera center around screening questions. They include ...

New President Appointed to Eli Lilly Canada
Canada NewsWire (press release), Canada - Jul 17, 2003
... Mr. Henderson succeeds Mr. Gaetano Crupi who has accepted the position
of Global Product Team Leader for Strattera(TM) (atomoxetine HCI). ...